Compare LOCL & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOCL | ALGS |
|---|---|---|
| Founded | 2021 | 2018 |
| Country | United States | United States |
| Employees | 333 | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.6M | 43.0M |
| IPO Year | N/A | 2020 |
| Metric | LOCL | ALGS |
|---|---|---|
| Price | $1.13 | $7.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $46.67 |
| AVG Volume (30 Days) | 23.0K | ★ 31.7K |
| Earning Date | 01-01-0001 | 06-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.30 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,186,000.00 |
| Revenue This Year | $36.93 | N/A |
| Revenue Next Year | $82.62 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.98 | $3.76 |
| 52 Week High | $5.75 | $13.69 |
| Indicator | LOCL | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 29.32 | 56.23 |
| Support Level | $0.98 | $7.61 |
| Resistance Level | $2.75 | $8.84 |
| Average True Range (ATR) | 0.13 | 0.55 |
| MACD | -0.00 | 0.15 |
| Stochastic Oscillator | 22.18 | 85.21 |
Local Bounti Corp is a controlled environment agriculture company. Its business model is based on building local facilities, operated by local teams, to deliver fresh and quality produce to local communities while maintaining a limited carbon footprint. Using proprietary technology to grow leafy greens and herbs in smart greenhouses with a cultivation process that uses less water and land than conventional agriculture, free from herbicides or pesticides, it delivers products that have a longer shelf life, and are good in taste.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.